The human immunodeficiency virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) epidemic has emerged as a major threat to public health. More than 250,000 persons have been diagnosed with AIDS and an estimated 1.5 million persons are infected with HIV in the U.S. Although originally an infection of gay white males in this country, increasingly HIV is infecting women, minority racial and ethnic populations, injecting drug users, and heterosexuals. An intensive basic and applied research effort has led to the clinical development of new HIV therapies at an accelerated pace. As new therapies come into use, data regarding appropriateness and effectiveness in the heterogeneous populations of patients for whom they are intended is often incomplete. A number of antiretroviral, antimicrobial, and ancillary therapies are currently available for managing HIV infection, and evidence suggests that the natural history of HIV disease has changed with the use of these drugs. To better assess the effectiveness and appropriateness of pharmaceutical therapies used in treating HIV disease, we propose to develop a comprehensive longitudinal database of individuals infected with HIV who are cared for in an urban primary setting. These data will be used to examine the effectiveness of antiretroviral and antimicrobial therapies in preventing progression of HIV disease and its opportunistic complications; to determine the association of surrogate laboratory markers with clinical outcomes; to delineate the frequency and consistency of prescription drug use and to identify sociodemographic and clinical characteristics of individuals with HIV associated with consistent use of, and response to, drug therapy. This database should serve as an important and rich resource to evaluate the evolving natural history of HIV infection treated with current and new pharmaceutical therapies.

National Institute of Health (NIH)
Agency for Healthcare Research and Quality (AHRQ)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (SRC)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
Schools of Medicine
United States
Zip Code
Walker Harris, V; Sutcliffe, C G; Araujo, A B et al. (2012) Hip bone geometry in HIV/HCV-co-infected men and healthy controls. Osteoporos Int 23:1779-87
Woreta, Tinsay A; Sutcliffe, Catherine G; Mehta, Shruti H et al. (2011) Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus. Gastroenterology 140:809-17
Brown, Todd T; Mehta, Shruti H; Sutcliffe, Catherine et al. (2010) Hepatic steatosis associated with increased central body fat by dual-energy X-ray absorptiometry and uncontrolled HIV in HIV/hepatitis C co-infected persons. AIDS 24:811-7
Sulkowski, Mark S; Mehta, Shruti H; Torbenson, Michael S et al. (2007) Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS 21:2209-16
Sulkowski, Mark S; Mehta, Shruti H; Torbenson, Michael et al. (2005) Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS 19:585-92
Mehta, Shruti H; Thomas, David L; Torbenson, Michael et al. (2005) The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. Hepatology 41:123-31
Kelleher, Thomas B; Mehta, Shruti H; Bhaskar, Ramakrishnan et al. (2005) Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol 43:78-84
Sulkowski, Mark S; Mehta, Shruti H; Chaisson, Richard E et al. (2004) Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS 18:2277-84
Mehta, Shruti H; Moore, Richard D; Thomas, David L et al. (2003) The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons. J Acquir Immune Defic Syndr 33:577-84
Yan, Yan; Hoover, Donald R; Moore, Richard D et al. (2003) Multivariate estimation of cumulative incidence, prevalence, and morbidity time of a disease when death is likely. J Clin Epidemiol 56:546-52

Showing the most recent 10 out of 30 publications